viewRedx Pharma PLC

Redx Pharma mark 'transformational year for the company with significant pipeline'

Redx Pharma's (LON:REDX) Lisa Anson presents the company's 'key progresses' made during their full year results for 2020. 

Anson marks a transformational year for the company with significant pipeline progression and further development of lead programmes in oncology and fibrosis.

She takes investors through, step by step, beginning with progress made on the Phase 1/2a trial of their lead oncology asset, RXC004, a potentially best-in-class, orally bioavailable, porcupine inhibitor. And RXC007 is expected to enter a Phase 1 study in H1 2021. 

The company has also announced the appointment of Dr Jane Robertson as Chief Medical Officer as well as significant deals made with AstraZeneca.

Quick facts: Redx Pharma PLC

Price: 62.5 GBX

Market: AIM
Market Cap: £171.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...


Redx Pharma £25.5m raise 'to drive forward our two key programmes, at pace'

Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive after announcing their conditional raise of around £25.5m. Anson says this raise puts Redx in a 'much stronger financial position which allows us to drive forward our two key programmes, at pace'. She goes on to explain the next...

on 7/12/20

2 min read